文献速递肝病

慢性丁型肝炎抗病毒治疗:临床试验与真实世界研究的新见解

Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies.
PubMed 文献 · Gut · 2025-04-07

慢性丁型肝炎是最严重的病毒性肝炎,进展为肝硬化和并发症风险更高。聚乙二醇干扰素α曾是唯一治疗选择,但病毒学应答率有限且耐受性差。2020年欧洲药品管理局批准bulevirtide 2 mg/日,临床试验和真实世界研究显示其单药治疗安全有效,联合聚乙二醇干扰素α可提高治疗期间HDV RNA检测不到率但不提高停药后应答率,且联合治疗可能诱导HBsAg清除。

要点

  • bulevirtide 2 mg/日是欧盟唯一获批的慢性丁型肝炎治疗药物
  • bulevirtide单药治疗在临床试验和真实世界研究中显示安全有效,包括肝硬化患者
  • bulevirtide联合聚乙二醇干扰素α提高治疗期间HDV RNA检测不到率,但不提高停药后应答率

核心结论

  • bulevirtide 2 mg/日单药治疗仍是慢性丁型肝炎唯一获批的疗法,至少在欧洲联盟地区如此。

研究设计与样本

  • 综述临床试验和真实世界研究数据。

主要发现

  • bulevirtide 2 mg/日单药治疗在临床试验和真实世界研究中显示安全有效,最长治疗144周,包括肝硬化患者。
  • 长期bulevirtide单药治疗可能减少肝硬化患者的失代偿事件。
  • 与聚乙二醇干扰素α单药治疗相比,bulevirtide 2 mg联合聚乙二醇干扰素α提高治疗期间HDV RNA检测不到率,但不提高停药后检测不到率。
  • 联合治疗而非bulevirtide单药治疗可能诱导部分患者HBsAg清除。
  • 聚乙二醇干扰素λ研究因肝脏毒性问题已终止;lonafarnib联合利托那韦在3期研究中显示有限的停药后疗效。

局限性

  • 聚乙二醇干扰素λ研究因肝脏毒性问题已终止。
  • lonafarnib联合利托那韦在3期研究中显示有限的停药后疗效。
  • 核酸聚合物治疗有前景但尚缺乏大型研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, carrying a greater risk of developing cirrhosis and its complications. For decades, pegylated interferon alpha (PegIFN-α) has represented the only therapeutic option, with limited virological response rates and poor tolerability. In 2020, the European Medicines Agency approved bulevirtide (BLV) at 2 mg/day, an entry inhibitor of hepatitis B virus (HBV)/hepatitis delta virus (HDV), which proved to be safe and effective as a monotherapy for up to 144 weeks in clinical trials and real-life studies, including patients with cirrhosis. Long-term BLV monotherapy may reduce decompensating events in patients with cirrhosis. The combination of BLV 2 mg with PegIFN-α increased the HDV RNA undetectability rates on-therapy but not off-therapy, compared with PegIFN monotherapy. However, combination therapy, but not BLV monotherapy, may induce hepatitis B surface antigen (HBsAg) loss in some patients. The PegIFN lambda study has been discontinued due to liver toxicity issues, while lonafarnib boosted with ritonavir showed limited off-therapy efficacy in a phase 3 study. Nucleic acid polymer-based therapy is promising but large studies are still lacking. New controlled trial data come from molecules, such as monoclonal antibodies and/or small interfering RNA, that target HBsAg or HBV RNAs, which demonstrated not only profound HDV suppression, but also HBsAg decline.While waiting for new compounds to be approved as monotherapy or in combination, BLV monotherapy 2 mg/day remains the only approved therapy for CHD, at least in the European Union region.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Lampertico P, Anolli MP, Roulot D, et al. Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies. Gut. 2025. PMID: 39663120. doi:10.1136/gutjnl-2024-332597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。